Prof. Mateo Aboy, PhD, SJD, CEng, FIP

Beyond the 510 (k): The regulation of novel moderate-risk medical devices, intellectual property considerations, and innovation incentives in the FDA’s De Novo pathway
Nature (npj) Digital Medicine 7 (1), 29

Mapping the patent landscape of medical machine learning
Nature Biotechnology 41 (4), 461-468

Mapping the Patent Landscape of Quantum Technologies: Patenting Trends, Innovation and Policy Implications
IIC-International Review of Intellectual Property and Competition Law 53(17) 8, 613-628

European patent protection for medical uses of known products and drug repurposing
Nature Biotechnology 40 (4), 465-471, 2022

Mapping the European patent landscape for medical uses of known products
Nature Biotechnology 39 (11), 1336-1343, 2021

The FDA De Novo medical device pathway, patents and anticompetition
Nature Biotechnology 39 (11), 1336-1343 2020

The Patentability of Computer-Implemented Simulations and Implications for Computer-Implemented Inventions (CIIs)
Journal of Intellectual Property Law & Practice 16 (7), 633-635, 2021

Standard contractual clauses for cross-border transfers of health data after Schrems II
Journal of Law and the Biosciences 8 (1), 2020

International transfers of health data between the EU and USA: a sector-specific approach for the USA to ensure an ‘adequate’ level of protectio
Journal of Law and the Biosciences, 2020

COVID-19 Contact Tracing Apps: A Stress Test for Privacy, the GDPR and Data Protection Regimes
Journal of Law and the Biosciences, 2020

Regulatory responses to medical machine learning
Journal of Law and the Biosciences, 2020

One year after Vanda, are diagnostics patents transforming into methods of treatment to overcome Mayo-based rejections?
Nature Biotechnology 38 (3), 279-283, 2020

Navigating Cross-Border Transfers in the Pharmaceutical Sector After Schrems II Invalidation of the EU-US Privacy Shield
European Pharmaceutical Law Review 4 (13, 153-160, 2020

The EU-US Privacy Shield Regime for Cross-Border Transfers of Personal Data under the GDPR
European Pharmaceutical Law Review 4 (1), 34-50, 2020

How does emerging patent case law in the US and Europe affect precision medicine?
Nature Biotechnology 37 (10), 1118-1125, 2019

Mayo’s impact on patent applications related to biotechnology, diagnostics and personalized medicine
Nature biotechnology 37 (5), 513-518, 2019

Was the Myriad decision a "surgical strike" on isolated DNA patents, or does it have wider impacts?
Nature biotechnology 36 (12), 1146-1149, 2018

After Myriad, what makes a gene patent claim "markedly different" from nature?
Nature biotechnology 35 (9), 820-825, 2017

Myriad's impact on gene patents
Nature biotechnology 34 (11), 1119, 2016